Brainomix: Business Overview, Financials & Competitive Analysis
Brainomix scores 8/10 on the AskCyborg Cyborg Score (Strong). Brainomix is a well-funded, clinically-validated AI medical imaging platform with proven real-world impact on stroke outcomes and expanding applications in pulmonary disease, positioned for significant US market expansion. In February 2026, Brainomix completed a Series C funding round totaling £18.8 million to accelerate US rollout of its AI-powered imaging platforms for.
What is Brainomix's industry? Brainomix (brainomix.com) operates in Diagnostic Imaging Equipment. AskCyborg classifies Brainomix under Diagnostic Imaging Equipment in its company registry.
Brainomix, a spinout from the University of Oxford, has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions. The comp...
Cyborg Score thesis
Brainomix is a well-funded, clinically-validated AI medical imaging platform with proven real-world impact on stroke outcomes and...
Read the full analyst-debate transcript →Get the Latest Brainomix Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBrainomix Overview
Pro stress-test →Brainomix, a spinout from the University of Oxford, has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions. The company's flagship product, Brainomix 360 Stroke, has been deployed to more than 300 hospitals and used in over 1.5 million patient cases across more than 20 countries. The platform has been associated with a 50% increase in the number of patients receiving mechanical thrombectomy, a procedure that can substantially reduce post-stroke disability.
Strategic Profile
Pro stress-test →Brainomix has built its commercial position on a body of clinical evidence that is unusual for an AI imaging company at this stage. New guidance from NICE, the globally respected health assessor, endorses the use of Brainomix 360 Stroke, with Brainomix being one of only two companies granted this highly coveted endorsement. The company is expanding beyond stroke into new therapeutic areas with similar unmet needs—harnessing AI to transform diagnosis and treatment where it matters most.
Competitive Landscape
Pro stress-test →Brainomix competes in the AI-powered medical imaging and stroke care decision-support space against companies developing similar diagnostic imaging solutions. Key competitors include vendors of radiology AI platforms and stroke imaging tools, though Brainomix differentiates through its comprehensive clinical validation evidence, NICE endorsement, FDA clearances, and demonstrated real-world impact on patient outcomes. The company's expansion into pulmonary fibrosis imaging positions it against broader medical imaging AI vendors.
Industry Context
Brainomix operates in Diagnostic Imaging Equipment.
Key facts
Founded: 2010 · Headquarters: Oxford, United Kingdom · Employees: 51-200